Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > G12C/G12V KRAS mutation in PC & CRC patients respond to Pela

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 18, 2023 1:40pm

115 Views

Post# 35641758

RE:RE:RE:RE:G12C/G12V KRAS mutation in PC & CRC patients respond to Pela

ONCYs pelareorep demonstrates to be effective in the knockdown of both KRAS (G12D/G12V KRAS mutations) and p53 gene activity, and ultimately effective in the treatment of pancreatic and GI cancers.

All the pre-clinical and clinical work on pelareorep in pancreatic, GI, and breast cancers. is now coming to fruition.

<< Previous

Bullboard Posts

Next >>

Three high-conviction small-cap stocks across the risk spectrum